22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      An Epigenome-Wide Association Study of Total Serum Immunoglobulin E Concentration

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immunoglobulin E (IgE) is a central mediator of allergic (atopic) inflammation. Therapies directed against IgE benefit hay fever 1 and allergic asthma 1, 2 . Genetic association studies have not yet identified novel therapeutic targets or pathways underlying IgE regulation 3- 6 . We therefore surveyed epigenetic association between serum IgE concentrations and methylation at loci concentrated in CpG islands (CGI) genome-wide in 95 nuclear pedigrees, using DNA from peripheral blood leukocytes (PBL). We validated positive results in additional families and in subjects from the general population. We show here replicated associations with a meta-analysis false discovery rate <10 −4 between IgE and low methylation at 36 loci. Genes annotated to these loci encode known eosinophil products, and also implicate phospholipid inflammatory mediators, specific transcription factors, and mitochondrial proteins. We confirmed that methylation at these loci differed significantly in isolated eosinophils from subjects with and without high IgE levels. The top three loci accounted for 13% of IgE variation in the primary subject panel, explaining 10 fold higher variance than that derived from large SNP GWAS 3, 4 . The study identifies novel therapeutic targets and biomarkers for patient stratification for allergic diseases.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

          Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophilic inflammation. They were randomly assigned (in a 1:1:1:1 ratio) to receive one of three doses of intravenous mepolizumab (75 mg, 250 mg, or 750 mg) or matched placebo (100 mL 0·9% NaCl) with a central telephone-based system and computer-generated randomly permuted block schedule stratified by whether treatment with oral corticosteroids was required. Patients received 13 infusions at 4-week intervals. The primary outcome was the rate of clinically significant asthma exacerbations, which were defined as validated episodes of acute asthma requiring treatment with oral corticosteroids, admission, or a visit to an emergency department. Patients, clinicians, and data analysts were masked to treatment assignment. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01000506. 621 patients were randomised: 159 were assigned to placebo, 154 to 75 mg mepolizumab, 152 to 250 mg mepolizumab, and 156 to 750 mg mepolizumab. 776 exacerbations were deemed to be clinically significant. The rate of clinically significant exacerbations was 2·40 per patient per year in the placebo group, 1·24 in the 75 mg mepolizumab group (48% reduction, 95% CI 31-61%; p<0·0001), 1·46 in the 250 mg mepolizumab group (39% reduction, 19-54%; p=0·0005), and 1·15 in the 750 mg mepolizumab group (52% reduction, 36-64%; p<0·0001). Three patients died during the study, but the deaths were not deemed to be related to treatment. Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma. GlaxoSmithKline. Copyright © 2012 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            DNA methylation profiling of human chromosomes 6, 20 and 22

            DNA methylation constitutes the most stable type of epigenetic modifications modulating the transcriptional plasticity of mammalian genomes. Using bisulfite DNA sequencing, we report high-resolution methylation reference profiles of human chromosomes 6, 20 and 22, providing a resource of about 1.9 million CpG methylation values derived from 12 different tissues. Analysis of 6 annotation categories, revealed evolutionary conserved regions to be the predominant sites for differential DNA methylation and a core region surrounding the transcriptional start site as informative surrogate for promoter methylation. We find 17% of the 873 analyzed genes differentially methylated in their 5′-untranslated regions (5′-UTR) and about one third of the differentially methylated 5′-UTRs to be inversely correlated with transcription. While our study was controlled for factors reported to affect DNA methylation such as sex and age, we did not find any significant attributable effects. Our data suggest DNA methylation to be ontogenetically more stable than previously thought.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tobacco-smoking-related differential DNA methylation: 27K discovery and replication.

              Tobacco smoking is responsible for substantial morbidity and mortality worldwide, in particular through cardiovascular, pulmonary, and malignant pathology. CpG methylation might plausibly play a role in a variety of smoking-related phenomena, as suggested by candidate gene promoter or global methylation studies. Arrays allowing hypothesis-free searches on a scale resembling genome-wide studies of SNPs have become available only very recently. Methylation extents in peripheral-blood DNA were assessed at 27,578 sites in more than 14,000 gene promoter regions in 177 current smokers, former smokers, and those who had never smoked, with the use of the Illumina HumanMethylation 27K BeadChip. This revealed a single locus, cg03636183, located in F2RL3, with genome-wide significance for lower methylation in smokers (p = 2.68 × 10(-31)). This was similarly significant in 316 independent replication samples analyzed by mass spectrometry and Sequenom EpiTyper (p = 6.33 × 10(-34)). Our results, which were based on a rigorous replication approach, show that the gene coding for a potential drug target of cardiovascular importance features altered methylation patterns in smokers. To date, this gene had not attracted attention in the literature on smoking. Copyright © 2011 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                28 November 2014
                18 February 2015
                30 April 2015
                30 October 2015
                : 520
                : 7549
                : 670-674
                Affiliations
                [1 ]Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA 02115
                [2 ]National Heart and Lung Institute, Imperial College, London SW3 6LY, UK
                [3 ]Université du Québec à Chicoutimi, Saguenay, Québec, Canada
                [4 ]Institute of Life Science, College of Medicine, Swansea University, SA2 8PP, UK
                [5 ]Ontario Institute for Cancer Research, Toronto, Ontario Canada, M5G 0A3
                [6 ]Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Canada ON M5S 1A1
                [7 ]University of Colorado School of Medicine and National Jewish Health, Denver, CO 80206
                [8 ]Department of Human Genetics, McGill University and Génome Québec Innovation Centre, Montréal, Canada
                [9 ]Jewish General Hospital and Lady Davis Research Institute, Montréal, Canada H3T 1E2
                [10 ]Department of Medical Sciences, SciLifeLab, Uppsala University, Uppsala, Sweden
                [11 ]Department of Medical Genetics, McGill University Health Centre, Montréal, Canada
                Author notes
                Address for Correspondence: Professor William O. C. Cookson, Imperial College London, Royal Brompton Campus, Guy Scadding Building, Dovehouse Street, London SW3 6LY, Phone: +44 20 7594 2943, w.cookson@ 123456imperial.ac.uk

                Author contributions: SWO, WOCC, GML and MFM planned the initial study. SWO, AB, KCW and MFM performed measurements of methylation status. LL and WOCC led statistical analyses of the data with SWO and GML: most analyses were carried out by LL. GML and TMP led discussions on replication strategy, methylation assays and cell-specific methylation, with input from MFM, DS and IY. EG validated Ilumina probes with bisulphite sequencing. CL led studies of SLSJ families with TH, and GD and JMH led studies of the PAPA subjects. CL led studies of isolated eosinophils. MH, LR and SB recruited subjects and studied lymphocyte subsets. WOCC wrote the first draft of the paper. All authors contributed to the interpretation of the results and the writing of the paper.

                [*]

                Contributed equally.

                Article
                EMS61290
                10.1038/nature14125
                4416961
                25707804
                9f12b533-5b8a-4b6a-b47a-6544bb2a48ad
                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article